Serina Therapeutics Appoints Joshua Thomas as VP of Chemistry to Advance POZ Platform
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 15 minutes ago0mins
- Leadership Expansion: Serina Therapeutics has appointed Dr. Joshua Thomas as Vice President of Chemistry, tasked with optimizing POZ platform-based drug candidates, aiming to enhance efficiency from discovery to development and strengthen the company's competitive edge in neurological disease treatments.
- Experienced Leadership: Dr. Thomas brings 13 years of scientific leadership experience from Mersana Therapeutics, where he contributed to the development of antibody-drug conjugate (ADC) technologies, which is expected to introduce innovative ideas and technical support to Serina's drug development efforts.
- Strategic Platform Advancement: His appointment will drive Serina's expansion of the POZ platform into two new therapeutic modalities, further enhancing market opportunities in small molecule drugs to meet the growing patient demand.
- Deepening Scientific Collaboration: Over the past two years, Dr. Thomas has positively influenced the evolution of the POZ chemistry platform while working closely with Serina as a consultant, and he will continue to promote the integration of scientific research with clinical applications moving forward.
SER.A
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on SER
Wall Street analysts forecast SER stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SER is 13.00 USD with a low forecast of 11.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.210
Low
11.00
Averages
13.00
High
15.00
Current: 3.210
Low
11.00
Averages
13.00
High
15.00
H.C. Wainwright
H.C. Wainwright
Buy
initiated
$15
2025-07-14
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$15
2025-07-14
initiated
Buy
Reason
H.C. Wainwright initiated coverage of Serina Therapeutics with a Buy rating and $15 price target. The firm says Serina is an emerging biopharmaceutical company focused on developing next-generation versions of existing active pharmaceutical ingredients.
Jones Trading
Justin Walsh
Strong Buy
Initiates
$11
2025-03-11
Reason
Jones Trading
Justin Walsh
Price Target
$11
2025-03-11
Initiates
Strong Buy
Reason
See All Ratings
About SER
Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
How did the company's recent strategic decisions impact its latest financial performance?
Can you explain the factors behind the recent changes in the company's stock price?
What are the expected impacts of current market trends on the company's future growth?
Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?